Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter S Winter

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual diseasePeter S Winter, Michelle L Ramseier, Andrew W Navia, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Cancer Research|December 2, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral HeterogeneityHannah L Williams, Andressa Dias Costa, Jinming Zhang, et al.
Cell|December 10, 2021
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancerSrivatsan Raghavan, Peter S Winter, Andrew W Navia, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Megan T Hoffman, Laleh Abbassi, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual diseasePeter S Winter, Michelle L Ramseier, Andrew W Navia, et al.
Nature Cancer|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trialKimberly J Perez, Andressa Dias Costa, Alexander Jordan, et al.
Cancer Research|December 2, 2022
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral HeterogeneityHannah L Williams, Andressa Dias Costa, Jinming Zhang, et al.
Cell|December 10, 2021
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancerSrivatsan Raghavan, Peter S Winter, Andrew W Navia, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Megan T Hoffman, Laleh Abbassi, et al.
Pageof 4